Investigational New Drugs

, Volume 32, Issue 3, pp 526–534

Phase II trial of vorinostat in advanced melanoma

  • N. B. Haas
  • I. Quirt
  • S. Hotte
  • E. McWhirter
  • R. Polintan
  • S. Litwin
  • P. D. Adams
  • T. McBryan
  • L. Wang
  • L. P. Martin
  • M. vonMehren
  • R. K. Alpaugh
  • J. Zweibel
  • A. Oza
PHASE II STUDIES

DOI: 10.1007/s10637-014-0066-9

Cite this article as:
Haas, N.B., Quirt, I., Hotte, S. et al. Invest New Drugs (2014) 32: 526. doi:10.1007/s10637-014-0066-9

Summary

Introduction Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma. Methods We evaluated 32 patients with advanced primary cutaneous or ocular melanoma in a multi-institutional setting (PMH Phase II Consortium) with continuous daily oral vorinostat 400 mg. The primary endpoint was response rate by RECIST, with time to progression as a secondary endpoint. The study was designed to distinguish a response rate of 20 % from a RR of 5 % and to distinguish a 2 month median progression-free survival (PFS), from one of 3.1 months. The study proceeded to stage 2 following 2 of 16 responses.. We also assessed VEGF, FGF levels, P52 polymorphisms and chromatin-associated proteins as potential biomarkers. Results Therapy was associated with significant side effects, including fatigue, nausea, lymphopenia, and hyperglycemia. Eleven patients experienced at least one grade 3 or higher adverse event. There were two confirmed PRs in patients with cutaneous melanoma. Sixteen patients had stable disease and 14 patients had progressive disease for best response. In addition, two patients with cutaneous melanoma scored as stable disease had early unconfirmed partial responses with subsequent progression. Patients with stable disease or partial response (n = 18) had a median progression free survival of 5 months. (range 2–12 months). Conclusions Vorinostat demonstrated some early responses and a high proportion of patients with stable disease, but did not meet its primary endpoint of response. Different schedules of this agent with BRAF mutation status and markers of histone acetylation could be explored in melanoma.

Keywords

Histone deacetylase inhibitor Melanoma Angiogenesis Chromatin associated proteins 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • N. B. Haas
    • 1
  • I. Quirt
    • 2
  • S. Hotte
    • 3
  • E. McWhirter
    • 3
  • R. Polintan
    • 2
  • S. Litwin
    • 4
  • P. D. Adams
    • 5
  • T. McBryan
    • 5
  • L. Wang
    • 2
  • L. P. Martin
    • 4
  • M. vonMehren
    • 4
  • R. K. Alpaugh
    • 4
  • J. Zweibel
    • 6
  • A. Oza
    • 2
  1. 1.University of PennsylvaniaPhiladelphiaUSA
  2. 2.Princess Margaret Cancer CentreTorontoCanada
  3. 3.Juravinski Cancer CentreHamiltonCanada
  4. 4.Fox Chase Cancer CenterPhiladelphiaUSA
  5. 5.University of GlasgowGlasgowUK
  6. 6.Clinical Trials Evaluation ProgramBethesdaUSA

Personalised recommendations